Abbott Laboratories

达纳

UBS Keeps Buy Rating, Raises PT to $31 from $28 on Abbott Laboratories.

Abbott Laboratories' Implied Fair Value Estimate Edges Higher Amid Legal Wins and Exact Sciences Deal Talk.

雅培

Abbott Laboratories stock price falls as MACD Death Cross and Bollinger Bands contract.

Abbott Laboratories Ownership Structure: Insights from Institutional Investors

Abbott Labs Sells Branded Generics Business to Mylan for 110M Shares

Catalyst<ul> <li>Most analysts rate ABT Buy, indicating institutional optimism despite differing views among analysts.</li></ul>Risk<ul> <li>Technical indicators show bearish signals are dominant with four bearish versus one bullish signal.</li> <li>Fund flows across all order sizes are trending negatively, suggesting lack of investor confidence.</li> <li>Technical indicators show the market is in a volatile state with no clear direction.</li></ul>

Key Factors

Abbott Laboratories announced a $25.7 billion acquisition of Exact Sciences in November 2025. Abbott's implied fair value estimate increased to $144.75, driven by legal wins and the pending Exact Sciences acquisition. UBS raised its price target for Abbott Laboratories to $31 from $28, maintaining a buy rating.

Recent Updates

ABT News